CSL, Australian company, licensed for business in Korea

Acquired permission to import medicines on the 16th and secured the rights to Afstyla

CSL, an Australian global pharmaceutical company, conducts full-scale marketing in Korea.

 

It was the first time in the domestic pharmaceutical industry to acquire a business license and an item license.

 

CSL Behring Korea, a subsidiary of CSL, received a drug import license from the MFDS on the 16th.

 

General manager, Ji-Young Sohn, who has served as the marketing and strategy planner of Korea Pfizer Pharmaceuticals and the head of the department of anti-cancer drugs at Roche Korea.

 

Sohn is a pharmaceutical management expert who graduated from the College of Pharmacy at Ewha Womans University and Korea University (MBA) Along with the business license, CSL Behring Korea also brought permission to approve ‘Afstyla’, a type A hemophilia treatment.

 

This product, which was licensed in January, was the first subsidiary of Zuellig Pharma Korea Ltd.

 

to be registered as a license holder.

 

This is because CSL Behring Korea did not obtain a business license, so Zanovex Korea acted as an item license.

 

However, recently, Afstyla's license for item approval has been changed to CSL Behring Korea.

 

Afstyla is now owned by CSL because it is generally assumed that the licensed company holds the copyright.

 

However, Afstyla will be sold by SK Plasma.

 

Unfortunately, Afstyla is a product developed by SK Chemicals, a subsidiary of SK Plasma, to preclinical and technically exported to CSL.

 

In March, it was approved for the marketing of the type B hemophilia treatment drug 'Idelvion'.

 

Janovex Korea is also registered as a license holder.

 

Idelvion will also be transferred to CSL Behring Korea in the near future.

 

CSL Behring is a global pharmaceutical company with hemophilia treatment and rare disease treatment, and is a subsidiary of the Australian CSL Group.

 

It has expanded into 60 countries worldwide and is headquartered in Pennsylvania, USA.

 

Afstyla and Idelvion, which have been licensed this time, are evaluated as drugs with a significantly improved half-life than conventional hemophilia drugs.

 

However, it is unlikely that the domestic market will be settled.

 

The size of the domestic hemophilia treatment market is about ₩180 billion, of which Type A treatment accounts for 80%, and the Green Cross is dominated.

 

In the case of Shire's highest-selling Adbate, Green Cross sells, and the second-largest product, 'Greengene F', is a product of Green Cross.

 

Pfizer's Benefix has the largest share of type B drugs.

 

In the case of hemophilia treatment, the Koham has great influence, so pharmaceutical companies with high contribution are currently leading the market.

 

In this situation, it is unclear whether CSL, a latecomer, will settle into the domestic market with only upgraded products.

 

This is because SK Plasma, a sales agent, is not a very influential pharmaceutical company in the domestic hemophilia treatment market.